Table 1.
Participant Demographics
| Somali (n = 70) | White (n = 69) | P-Value | |||||
|---|---|---|---|---|---|---|---|
| Male | Female | Male | Female | Race | Sex | R×S | |
| N | 36 | 34 | 37 | 32 | --- | 0.796 | --- |
| Age (yrs) | 30± 10 | 27 ± 9 | 33 ± 9 | 29 ± 8 | 0.135 | 0.019 | 0.799 |
| BMI (kg/m2) | 29 ± 7 | 27 ± 8 | 29 ± 4 | 26 ± 6 | 0.580 | 0.035 | 0.743 |
| Seated SAP (mmHg) | 122 ± 13 | 112 ± 10 | 124 ± 12 | 113 ± 11 | 0.353 | < 0.001 | 0.665 |
| Seated DAP (mmHg) | 75 ± 9 | 74 ± 7 | 77 ± 12 | 73 ± 9 | 0.710 | 0.128 | 0.257 |
| Seated HR (beat/min) | 68 ± 13 | 71 ± 12 | 68 ± 11 | 70 ± 11 | 0.679 | 0.206 | 0.841 |
| Disease, n (%) | |||||||
| None | 22 (61) | 30 (88) | 32 (86) | 25 (78) | 0.963 | 0.091 | 0.199 |
| Cardiovascular | 3 (8) | 0 (0) | 2 (5) | 0 (0) | 0.661 | 0.030 | 0.162 |
| Pulmonary | 6 (17) | 3 (9) | 7 (19) | 3 (9) | 0.779 | 0.135 | 0.510 |
| Metabolic/ | 8 (22) | 1 (3) | 2 (5) | 4 (13) | 0.429 | 0.245 | 0.041 |
| Endocrine | |||||||
| Renal | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0.319 | 0.340 | 0.410 |
| Medication, n (%) | |||||||
| None | 29 (81) | 32 (94) | 36 (97) | 21 (66) | 0.455 | 0.151 | < 0.001 |
| AngII Antagonist | 3 (8) | 0 (0) | 0 (0) | 0 (0) | 0.082 | 0.096 | 0.032 |
| Biguanide | 5 (14) | 1 (3) | 0 (0) | 3 (9) | 0.312 | 0.850 | 0.073 |
| β- Antagonist | 1 (3) | 0 (0) | 1 (3) | 0 (0) | 0.568 | 0.620 | 0.820 |
| Glucocorticoid | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0.319 | 0.340 | 0.410 |
| Hormone Replacement | 2 (6) | 0 (0) | 0 (0) | 0 (0) | 0.082 | 0.620 | 0.309 |
| Oral Contraceptive | --- | 1 (3) | --- | 9(28) | 0.023 | --- | --- |
| Statin | 2 (6) | 1 (3) | 0 (0) | 1 (3) | 0.317 | 0.918 | 0.567 |
Results are means ± SD or reported prevalence (percentage); SAP, Systolic Arterial Pressure; DAP, Diastolic Arterial Pressure; HR, Heart Rate, AngII, Angiotensin II; BMI, body mass index.